A Preliminary Assessment of Macular Function by MF-ERG in Myopic Eyes with CNV with Complete Response to Photodynamic Therapy

2003 ◽  
Vol 13 (5) ◽  
pp. 461-467 ◽  
Author(s):  
M.N. Moschos ◽  
D. Panayotidis ◽  
M.M. Moschos ◽  
Chr. Bouros ◽  
P.G. Theodossiadis ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Electrical Response ◽  
Multifocal Electroretinogram ◽  
Complete Response ◽  
Post Treatment ◽  
Pathologic Myopia ◽  
Macular Function ◽  
Before And After ◽  
Visual Acuity Testing

Purpose To evaluate by multifocal electroretinogram (MF-ERG) macular function before and after photodynamic therapy (PDT) in myopic eyes with choroidal neovascularization (CNV). Patients and Methods Ten eyes with classic subfoveal CNV due to pathologic myopia were studied with MF-ERG before and after PDT in order to evaluate the results of PDT with verteporfin. The post-treatment follow-up was 6 months. Visual acuity testing, ophthalmic examinations, fluorescein and indocyanine green angiograms, and MF-ERG recordings were used to evaluate the results of PDT with verteporfin. The post-treatment period was 6 months. Results Before treatment, the electrical response densities in the foveal and perifoveal areas were apparently decreased in all patients. Six months after treatment, the mean retinal response densities in the same areas were found to be higher than before treatment. Conclusions MF-ERG evaluates objectively the macular function in myopic eyes with CNV. After successful PDT, the electrical activity of the foveal and parafoveal areas is higher than before treatment. This finding postulates the efficacy of PDT in the treatment of CNV.

scholarly journals Photodynamic therapy of subfoveal choroidal neovascularization

2007 ◽  
Vol 135 (11-12) ◽  
pp. 629-634
Author(s):  
Ana Georgijevic ◽  
Zoran Tomic
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Blood Vessels ◽  
Choroidal Neovascularization ◽  
Retinal Pigment ◽  
Photochemical Reactions ◽  
Pathologic Myopia ◽  
Target Tissue ◽  
Choroidal Hemangioma

Introduction Photodynamic therapy (PDT) is a method of treatment of choroidal neovascularization (CNV) with a diode laser used after intravenously administered verteporfin. Verteporfin is a light-activated drug initiating photochemical reactions in the target tissue. This leads to the selective occlusion of blood vessels in the CNV with no damage of photoreceptors, retinal pigment epithelium and retinal blood vessels. Objective To show the results of the treatment of predominantly classic subfoveal CNV with PDT with verteporfin used for the first time in our country. Method From 2003 to 2005, we treated 15 eyes in 15 patients using PDT and verteporfin, because of predominantly classic subfoveal CNV. If macular oedema was present as proved by fluorescein angiography, triamcinolone was administered intravitreally after PDT. Average follow-up period was 7 months (3 months to 2 years). Study design: retrospective, noncomparative, consecutive case series. Results Two thirds of patients had CNV due to AMD, while in others it was caused by pathologic myopia, chorioretinitis, angioid streaks, choroidal hemangioma, except for one patient who had idiopathic CNV. Visual acuity was stabile in 60% (9/15) of patients, of whom in 60% (6/10) of patients with AMD, as well as in patients with pathologic myopia, idiopathic CNV and choroidal hemangioma. Retreatment with PDT was indicated in 40% (6/15) and in 50% (5/10) of patients with AMD, mostly 4-6 months after first PDT, but was done only in one patient (economic reasons). In two patients with AMD, triamcinolone was administered intravitreally for 2-4 months, which resulted in the stabilization of visual acuity. Conclusion Visual acuity was stabile in 60% of all treated patients with predominantly classic subfoveal CNV after only one application of PDT with verteporfin during the average follow-up of 7 months (3 months to 2 years). Retreatment was indicated in 40% of the treated patients, and in 50% of patients with AMD. As confirmed, intravitreal administration of triamcinolone after PDT could stabilize visual acuity. Side effects were not noticed.

scholarly journals P0429OUTCOMES OF LUPUS NEPHRITIS OVER AN ERA OF EVOLVING IMMUNOSUPPRESSION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Jason McMinn ◽  
Colin C Geddes ◽  
Emily McQuarrie
Keyword(s):  
Lupus Nephritis ◽  
Electronic Patient Record ◽  
Immunosuppressive Treatment ◽  
Complete Response ◽  
Histopathological Diagnosis ◽  
Class V ◽  
Remission Rates ◽  
Induction Regimen ◽  
Before And After

Abstract Background and Aims The reported incidence of lupus nephritis (LN) is approximately 6.1 cases per million population per year in Scotland based on Scottish Renal Registry biopsy data. Despite immunosuppressive treatment, approximately 10-30% of patients will progress to established renal failure (ERF) within 15 years. In December 2007, our unit moved from a protocol of Cyclophosphamide/ steroid induction with Azathioprine/ Prednisolone maintenance to Mycophenolate/ steroid induction and maintenance. We undertook this study to compare remission rates before and after this change. Method A retrospective electronic patient record analysis was performed for all patients in our centre with a documented native renal biopsy showing a histopathological diagnosis of LN, between 1 July 1993 and 31 December 2017. Repeat biopsies were excluded. Baseline demographics, histopathological class and first and second line induction and maintenance therapies were recorded. Endpoints analysed were; partial and complete response (as defined in KDIGO Clinical Practice Guideline for Glomerulonephritis 2012), time to achieve this response, relapse, progression to ERF and death. Results 120 patients who underwent a biopsy during the 24.5-year period received a diagnosis of lupus nephritis. 82.5% of patients were Caucasian. Median duration of follow-up was 72 months. 15% of patients died and 5% developed ERF within the follow-up period, representing one death per 56 patient years and one incident case of ERF per 168 patient years. There were 40 patients in the pre-December 2007 group and 80 in the post-December 2007 group. Those in the earlier group were younger, with a mean age of 35.4 years versus 44.8 years in the later group (p=0.002). 23% had class V in the earlier group compared to 15% in the later group (p=0.31). Proportions of female patients were 80% and 75% in the early and late groups respectively (p=0.54). Median creatinine was 106µmol/L in the pre-December 2007 group and 89.5 µmol/L in the post-December 2007 group (p=0.96). Patients in the pre- and post- December 2007 groups had comparable rates of complete response, at 72% and 71% respectively. However, those diagnosed before December 2007 were slower to respond, with a median time to achieve complete response of 10.5 months, compared to 6 months in those diagnosed after 1 December 2007 (p=0.007). Conclusion Following a change in our immunosuppressive induction regimen from Cyclophosphamide/ steroids to Mycophenolate/ steroids, our response rates have remained similar, however speed of attaining remission has improved.

scholarly journals Assessment of the Efficacy of Photodynamic Therapy in Patients with Chronic Central Serous Chorioretinopathy

2020 ◽  
Vol 75 (6) ◽  
pp. 298-308
Author(s):  
Kateřina Manethová ◽  
Jan Ernest ◽  
Michal Hrevuš ◽  
Naďa Jirásková
Keyword(s):  
Photodynamic Therapy ◽  
Central Serous Chorioretinopathy ◽  
Functional Results ◽  
University Hospital ◽  
Prospective Clinical Study ◽  
Chronic Central Serous Chorioretinopathy ◽  
Chronic Form ◽  
Before And After ◽  
The Mean

Purpose: The aim of this prospective clinical study was to evaluate the anatomical and functional results of the treatment of 54 eyes with chronic form of central serous chorioretinopathy (CSC) using photodynamic therapy in a reduced (half) verteporfin (HD-PDT) dosing regimen. Materials and Methods: Our prospective study included 54 eyes of 52 patients (40 males, 12 females) at an average age of 50.1 years (median 49.5, range 30–75 years) treated at the Ophthalmology Clinic of the First Faculty of Medicine and Military University Hospital in Prague from January 2012 to January 2018 for chronic form of CSC with a minimum disease duration of 3 months. In our study, we evaluated the improvement of the best corrected visual acuity (BCVA) and central retinal thickness (CRT) before treatment and at 1, 3, 6 and 12 months after HD-PDT. Results: The mean baseline BCVA was 68.91 ± 10.5 ETDRS letters (median 71; range 35–85) and the mean baseline CRT was 385.6 ± 118.5 µm (median 367, 5 µm; range 245–1000 µm). At the end of the follow-up period, the average BCVA was 79 ± 11 ETDRS letters (median 82; range 38–93). The improvement in BCVA before and after treatment was statistically significant in all measurements (p < 0.0001). The mean CRT at the end of the follow-up period was 263.5 ± 52 µm (median 258.5 µm; range 162–404 µm). The decrease in CRT at all timepoints was statistically significant compared to baseline (p < 0.0001). In our set of patients, at the end of the follow-up period, the retinal finding was improved or stabilized in 50 eyes (92.6 %). In this study, we observed in 2 cases the development of secondary choroidal neovascularization (CNV). Conclusion: HD-PDT is a long-term safe and effective method of treating chronic forms of CSC. However, despite a reduced dose of verteporfin, complications may occur.

scholarly journals Photodynamic Therapy of Malignant Brain Tumours

1990 ◽  
Vol 17 (2) ◽  
pp. 193-198 ◽  
Author(s):  
Paul J. Muller ◽  
Brian C. Wilson
Keyword(s):  
Photodynamic Therapy ◽  
Median Survival ◽  
Brain Tumours ◽  
Complete Response ◽  
Tumour Resection ◽  
Malignant Tumours ◽  
Actuarial Survival ◽  
Malignant Brain Tumours ◽  
Actuarial Survival Rate

ABSTRACT:Fifty patients with malignant supratentorial tumours were treated with intra-operative photodynamic therapy (PDT); in 33 cases the tumour was recurrent. In 45 patients the tumour was a cerebral glioma and in 5 cases a solitary cerebral metastasis. All patients received a porphyrin photosensitizer 18-24 hours pre-operatively. Photoillumination was carried out at 630 nm to a tumour cavity created by radical tumour resection and/or tumour cyst drainage. The light energy density ranged from 8 to 175 J/cm2. In 8 patients additional interstitial light was administered. The operative mortality was 4%. Follow up has ranged from 1 to 30 months. The median survival for the 45 primary malignant tumours was 8.6 months with a 1 and 2 year actuarial survival rate of 32% and 18%, respectively. In 12 patients a complete or near complete CT scan response was identified post PDT. These patients tended to have a tumour geometry (eg. cystic) that allowed complete or near complete light distribution to the tumour. The median survival for this group was 17.1 months with a 1 and 2 year actuarial survival of 62% and 38%, respectively. In the 33 cases who did not have a complete response the median survival was 6.5 months with a 1 and 2 year actuarial survival of 22% and 11%, respectively. Photodynamic therapy of malignant brain tumours can be carried out with acceptable risk. Good responses appear to be related to adequate light delivery to the tumour.

High Risk Hairy Cell Leukemia (HCL) Treatment with Fludarabine: Report of Three Cases with Low Toxicity and Durable Responses.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4769-4769
Author(s):  
Antonio A. Carrasco-Yalan ◽  
Olga M. López-Odría ◽  
Luis Riva-Gonzales ◽  
Pilar Quiñones-Avila ◽  
Fernando Cauvi-R ◽  
...  
Keyword(s):  
High Risk ◽  
B Cell ◽  
Blood Count ◽  
B Lymphocyte ◽  
Complete Response ◽  
Post Treatment ◽  
Current Therapy ◽  
Cell Leukemia ◽  
Count Recovery

Abstract HCL is a chronic leukemia of B-lymphocyte with variable clinical course: symptomatic cytopenia and/or marked splenomegaly. Concomitant infections disease are often and transfusion are quite necessary. Current therapy includes interferon, 2′deoxycoformycin, 2′chlorodeoxyadenosine which induce profound and durable CD4 and CD8 T cells cytopenia inducing major infection risk. Fludarabine phosphate (F-AMP) had been extensively used in chronic B-cell leukemia and lymphomas; previous reports have shown response in pre-treated HCL patients (Kraut, 1991; Kantarjian, 1991). Herein we show our experience with 3 high risk-HCL patients treated with F-AMP in our institution between May 2001 and August 2002. Pt 1: male 52 yo, debuted with splenomegaly (200 mm) and pancytopenia in 12/2000. Massive HCL involment in bone marrow (BM), flow showed positivity to CD20, CD 11c, CD 25 and CD103; TRAP test positive. At that point patient was at first splenectomized, with transient moderate blood count recovery. Five months later patient showed severe cytopenia and was started on F-AMP 25mg/m2 i.v. d1-5 each 28 days 6 cycles. Patient got complete haematological response with residual infiltration for HCL in BM; with a follow up of 51 months after F-AMP without cytopenias and infections. Pt 2: male, 53 yo, debuted with splenomegaly (over 200 mm), pancytopenia and diffuse B-cell BM involvement in 03/2002. Lucid spleen spots were observed at CT scan, followed by fever and haemolytic anemia. Splenectomy was performed, final diagnosis included extra-pulmonary TBC for M. Tuberculosis and HCL. Flow showed: CD20 (+), CD11c (+), CD 25(+), CD103 (+), CD5 (−), CD10 (−); TRAP test positive. TBC treatment started and mild blood count recovery was observed, 10 months after splenectomy; villous lymphocytes appeared in peripheral blood. Patient was started on F-AMP 25mg/m2 i.v. d1-5 each 28 days 6 cycles. Patient got Complete Response (CR) with a follow up of 40 months without leukaemia or infection recurrence. Pt 3: male 63 yo, with previous medullar thyroid carcinoma diagnosis three years ago. He debuted with splenomegaly (200 mm), mild cytopenia and serum creatinine 1.26 mg/dl by 01/2002. Typical HCL involvement in BM, flow showed positivity to CD20, CD 11c, CD 25 and CD103. Patient was started on F-AMP 25mg/m2 i.v. d1-5, one cycle (08/2002). Ten weeks later, previous to restart treatment a BM assessment showed CR with creatinine clearance range between 30–40 ml/min, therapy was stopped. Actually with a follow up of 36 months patient is without recurrence. Our experience strongly suggests and confirms potential role of F-AMP, in the management of high risk HCL previously splenectomized or post infection disease. Interestingly one patient responded to a total dose of 125mg/m2. Base in our and others data, F-AMP should be considered for HCL treatment. Table: Blood counts at diagnosis and 6 months post treatment Neutrophils Platelets Hb mpt = months post treatment Pt 1 Dx 225 22 K 6.5 6 mpt 4450 213 K 16.2 Pt 2 Dx 686 57 K 8.3 6 mpt 2750 251 K 16.2 Pt 3 Dx 1330 331 K 11.6 6 mpt 3400 176 K 12.4

Photodynamic therapy for palliation of locally recurrent breast carcinoma.

1987 ◽  
Vol 5 (11) ◽  
pp. 1766-1770 ◽  
Author(s):  
M Schuh ◽  
U O Nseyo ◽  
W R Potter ◽  
T L Dao ◽  
T J Dougherty
Keyword(s):  
Photodynamic Therapy ◽  
Breast Carcinoma ◽  
Chest Wall ◽  
Complete Response ◽  
Chest Wall Recurrence ◽  
Heavily Pretreated ◽  
Locally Recurrent ◽  
Recurrent Breast ◽  
Lost To Follow Up

Fourteen women with locally recurrent breast carcinoma on the chest wall following mastectomy were given 30 courses of photodynamic therapy (PDT). All patients had been heavily pretreated with conventional modes of therapy (radiation therapy, chemotherapy, hormonal therapy, surgical resection). Twenty-two courses yielded a partial response; two courses yielded a complete response; four courses showed no response; one patient was treated as an adjunct to surgery; and one patient was lost to follow-up. Duration to response was variable, ranging from 6 weeks to 8 months. Several women had chest wall disease controlled for prolonged periods of time using repeated courses of PDT. Two women had re-epithelialization of ulcerated lesions. Complications were minimal and included pain (two patients), sunburn (two), and infection (one). These results suggest that treatment with PDT can aid in local control of chest wall recurrence following mastectomy in selected patients.

scholarly journals Long Term Effectiveness of Photodynamic Therapy for CIN Treatment

2019 ◽  
Vol 12 (3) ◽  
pp. 107 ◽  
Author(s):  
Natalia Mayumi Inada ◽  
Hilde Harb Buzzá ◽  
Marieli Fernanda Martins Leite ◽  
Cristina Kurachi ◽  
Jose Roberto Trujillo ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Photodynamic Therapy ◽  
Placebo Group ◽  
Cervical Intraepithelial Neoplasia ◽  
Intraepithelial Neoplasia ◽  
Complete Response ◽  
Incidence Rates ◽  
South Central

(1) Background: Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer death in women worldwide. The highest incidence rates are in Africa, followed by South-Central Asia and South America. According to the Brazilian National Institute of Cancer (INCA), 16,370 new cases of cervical cancer were estimated for each year of the biennium of 2018–2019. About 90% of cervical cancers originate from the malignant progression of cervical intraepithelial neoplasia (CIN) which is classified based on cytohistological characteristics (low- and high-grade lesions). The present study reports the long-term effectiveness of topical photodynamic therapy (PDT) for CIN grades 1 and 2/3 with up to two years of follow up. (2) Methods: A total of 56 patients with CIN 1, ten with CIN 2, and 14 patients for the placebo group were enrolled in this study. (3) Results: 75% (n = 42) of CIN 1 patients presented a complete response to PDT and only 23.2% (n = 13) of recurrence, progression, and/or lesions remaining two years after PDT. For CIN 2/3 patients, 90% were observed to be cured after one and two years of follow up. (4) Conclusions: PDT presented best results two years after a non-invasive, fast, and low-cost procedure and in comparison with the placebo group, preventing the progression of cervical intraepithelial neoplasia and preserving the cervix.

Sign in / Sign up

Export Citation Format

Share Document